Data analyses from The Cancer Genome Atlas (TCGA) indicate that high expression of the IL-12/STAT4 axis is associated with better survival rates in breast cancer patients, especially in more aggressive subtypes, while reduced STAT4 expression correlates with poorer prognoses [49]. This evidence concerns the gene STAT4 and breast cancer.